Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT06049745
Starting soon Phase 4

Use of Misoprostol in Hysteroscopic Myomectomy

NCT06049745 · tracked via the Priya Life Science Israel tracker
Sponsor
Assuta Ashdod Hospital
Phase
Phase 4
Started
2023-11
Last updated
2023-09-22

Condition(s) studied

Hysteroscopic Myomectomy

Investigational drug(s) / intervention(s)

Misoprostol 400 Microgram Oral Tablet

Misoprostol 400 Microgram Oral Tablet: S.L misoprostol 400 mcg

Study summary

Hysteroscopic myomectomy is typically suitable for myomas measuring under 4 cm in size. The utilization of misoprostol before the procedure can facilitate uterine access, decrease fluid absorption, and reduce blood loss, consequently leading to a decrease in the overall procedure time. In this randomized trial, the investigators aim to investigate the impact of misoprostol administration and its effects on each of the mentioned parameters.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * women between the ags of 20 years- 55 years, inclusive * undergoing hysteroscopic myomectomy * submucosal fibroid less than 40 mm (type 0, 1 and 2) * up to 2 submucosal fibroids * patients are able to provide written informed consent Exclusion Criteria: * post menopausal women * inability to perform operative hysteroscopy under anesthesia in the past due to cervical stenosis * previous PID or documented tubal occlusion * positive BHCG test * inability to consent due to cognitive or language barrier * allergy to misoprostole * severe COPD, asthma or cardiac disease

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Assuta Ashdod University Hospital Ashdod Israel

More Assuta Ashdod Hospital trials in Israel

Screening for Fibromyalgia Among Patients With Suspected Endometriosis Recruiting
Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Benign Vaginal Gynecologic Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06049745 on ClinicalTrials.gov ↗ ← All trials in Israel